Hypersensitivity to ticagrelor and low response to clopidogrel: a case report

Ticagrelor is widely used to treat acute coronary syndrome. Hypersensitivity reaction of ticagrelor is rarely recognized. A low response to clopidogrel, which occurs in up to 23% of patients, is an independent risk factor for stent thrombosis. Management of patients with a low response to clopidogre...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Jing, Lyu, Shuzheng, Ge, Changjiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287072/
https://www.ncbi.nlm.nih.gov/pubmed/28154807
http://dx.doi.org/10.5415/apallergy.2017.7.1.51
_version_ 1782504100899848192
author Dai, Jing
Lyu, Shuzheng
Ge, Changjiang
author_facet Dai, Jing
Lyu, Shuzheng
Ge, Changjiang
author_sort Dai, Jing
collection PubMed
description Ticagrelor is widely used to treat acute coronary syndrome. Hypersensitivity reaction of ticagrelor is rarely recognized. A low response to clopidogrel, which occurs in up to 23% of patients, is an independent risk factor for stent thrombosis. Management of patients with a low response to clopidogrel and ticagrelor hypersensitivity who are undergoing antithrombotic therapy remains to be a challenge. Herein, we report a patient with low response to clopidogrel and ticagrelor hypersensitivity, who was successfully managed using aspirin and warfarin.
format Online
Article
Text
id pubmed-5287072
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Asia Pacific Association of Allergy, Asthma and Clinical Immunology
record_format MEDLINE/PubMed
spelling pubmed-52870722017-02-02 Hypersensitivity to ticagrelor and low response to clopidogrel: a case report Dai, Jing Lyu, Shuzheng Ge, Changjiang Asia Pac Allergy Case Report Ticagrelor is widely used to treat acute coronary syndrome. Hypersensitivity reaction of ticagrelor is rarely recognized. A low response to clopidogrel, which occurs in up to 23% of patients, is an independent risk factor for stent thrombosis. Management of patients with a low response to clopidogrel and ticagrelor hypersensitivity who are undergoing antithrombotic therapy remains to be a challenge. Herein, we report a patient with low response to clopidogrel and ticagrelor hypersensitivity, who was successfully managed using aspirin and warfarin. Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2017-01 2017-01-26 /pmc/articles/PMC5287072/ /pubmed/28154807 http://dx.doi.org/10.5415/apallergy.2017.7.1.51 Text en Copyright © 2017. Asia Pacific Association of Allergy, Asthma and Clinical Immunology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Dai, Jing
Lyu, Shuzheng
Ge, Changjiang
Hypersensitivity to ticagrelor and low response to clopidogrel: a case report
title Hypersensitivity to ticagrelor and low response to clopidogrel: a case report
title_full Hypersensitivity to ticagrelor and low response to clopidogrel: a case report
title_fullStr Hypersensitivity to ticagrelor and low response to clopidogrel: a case report
title_full_unstemmed Hypersensitivity to ticagrelor and low response to clopidogrel: a case report
title_short Hypersensitivity to ticagrelor and low response to clopidogrel: a case report
title_sort hypersensitivity to ticagrelor and low response to clopidogrel: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287072/
https://www.ncbi.nlm.nih.gov/pubmed/28154807
http://dx.doi.org/10.5415/apallergy.2017.7.1.51
work_keys_str_mv AT daijing hypersensitivitytoticagrelorandlowresponsetoclopidogrelacasereport
AT lyushuzheng hypersensitivitytoticagrelorandlowresponsetoclopidogrelacasereport
AT gechangjiang hypersensitivitytoticagrelorandlowresponsetoclopidogrelacasereport

Ejemplares similares